April 24 (Reuters) - GENEURO SA GNRO.PA :
* GENEURO: FINANCIAL INFORMATION AND BUSINESS UPDATE FOR THE
FIRST
QUARTER 2019
* Q1 CASH POSITION OF €13.3 MILLION, INCLUDING €5.0 MILLION
FROM
CREDIT FACILITY
* FINAL 12-MONTH RESULTS FROM PHASE 2A TYPE 1 DIABETES TRIAL
EXPECTED Q2 2019
* SUCCESSFUL ANGEL-MS PHASE 2B EXTENSION STUDY RESULTS
CONFIRM AND
EXTEND NEUROPROTECTIVE EFFECTS OF TEMELIMAB IN MS
* COMPANY RECOGNIZED €57.5K IN MANAGEMENT FEE REVENUES IN
THE
FIRST QUARTER OF 2019
Source text for Eikon: ID:nBw80njJCa
Further company coverage: GNRO.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))